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Abstract 
Magnetic nanocomposites are a class of smart materials that have attracted recent 
interest as drug delivery systems or as medical implants. In this study, meltable 
nanobiocomposites (NBC) composed of biocompatible dextran fatty acid ester and 
magnetic nanoparticles (MNPs) melting close to human body temperature were 
prepared and loaded with Rhodamine B (RhB) or green fluorescent protein (GFP) 
as model drugs to evaluate their potential use as drug delivery system. The release 
of the model drugs from the magnetic NBC investigated under the influence of a 
high frequent alternating magnetic field (AMF, 20 kA/m at 400 kHz) showed that 
on-demand release is realized applying the external AMF. The NBC showed a long-
term stability (28 d) of the incorporated iron oxide particles after incubation in 
artificial body fluids. This work reveals the potential of the NBC as a drug carrier.  
Keywords: Dextran ester; magnetic nanobiocomposite; alternating magnetic field; 
controlled release; biodegradation  
 
INTRODUCTION 
Magnetic composites, consisting of magnetic 
particles and usually an organic matrix, have been used 
for remote controlled drug delivery (temporal and/or 
spatial) [1]. The organic matrices are often hydrogels 
composed of polymer networks containing large 
amount of water or biological fluids. Intensive studies 
have been reported on composites of thermo-
responsive hydrogels, which are switched on/off 
through the heat generated by a magnetic stimulus [2-
4]. In most cases, the drugs are released from the 
hydrogels above lower critical solution temperature 
(LCST) [5,6]. Nevertheless, magnetic hydrogels have 
certain shortcomings including leaking of drug, low 
biocompatibility, and long relaxation times [7]. 
Thermoplastic materials are used as an alternative 
matrix to overcome the limitations of hydrogels for 
controlled release applications. The drug release is 
remote controlled by increasing the temperature to 
induce the glass transition or the melting of the 
material. Examples of such systems include low 
molecular compounds like monoglyceride-based 
thermo-responsive drug delivery system [8], polymer-
based implants using poly(methyl methacrylate) 
(PMMA) [9], or poly(D,L-lactic acid) based drug 
delivery systems [10]. However, PMMA is not 
biodegradable. Regarding poly(D,L-lactic acid), 
hydrolysis of polymer may lead to immunologic 
responses in the human body [11]. Thus, polymers 
without these shortcomings are highly desired for 
advanced drug delivery. 
Dextran, a polysaccharide used in various medical 
applications [12], could be transferred by esterification 
with fatty acid into thermoplastic materials [13]. The 
melting temperature of fatty acid esters of dextran 
could be controlled by adjusting the type of fatty acid 
and the degree of substitution (DS). It is even possible 
to prepare dextran esters that melts near the human 
body temperature. Moreover, dextran ester yields 
homogeneous and transparent melts, which form stable 
films on a broad variety of materials. The transparency 
enables even the optical detection of the distribution of 
the loaded magnetic nanoparticles (MNPs) in µm-scale 
[14]. It could be demonstrated that these 
nanobiocomposites (NBC) can be molten with an 
external high frequent alternating magnetic field 
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(AMF), enabling the possibility for the remote-
controlled release of immobilized compounds. 
In a recent study, it was shown that release of 
green fluorescent protein (GFP) from magnetic 
nanobiocomposite (NBC) was accelerated by 
continuous exposure to AMF [14]. GFP was chosen 
because it is widely used as a biomarker and it is 
applied as an indicator for protein release, too [15,16]. 
Rhodamine B (RhB) has also been widely reported as 
model drug in controlled release applications. It was 
used to simulate a water-soluble drug [17,18]. In the 
present work, both compounds were loaded separately 
into dextran fatty ester-MNP forming NBC and the 
release of the model drugs was determined by 
spectroscopic methods under the influence of heat 
produced by simple external heating or by internal 
heating applying an alternating magnetic field (AMF). 
Additionally, the iron release from the incorporated 
MNPs was assessed as a measure for the stability of 
these composites under different physiological 
conditions using different artificial body fluids. 
MATERIALS AND METHODS 
Materials 
Dextran myristic acid ester (degree of 
substitution, DS = 2.76, Mw = 22 000 g/mol) and 
dextran palmitic acid ester (DS = 2.69,                           
Mw = 19 000 g/mol) were prepared by conversion of 
dextran produced by Leuconostoc mesenteroides ssp. 
(6000 g/mol) with fatty acid iminium chlorides, which 
were obtained by activation of the fatty acid with 
DMF/oxalyl chloride according to the procedure 
described in reference [13]. Magnetic nanoparticles 
(NMPs) were prepared from a solution of 
FeCl2x4H2O/FeCl3x6H2O by the basic precipitation 
process. The MNPs were coated with oleic acid in a 
ball mill (Pulverisette 5, Fritsch, Germany) for 2 h and 
150 rpm as described in reference [19]. Green 
fluorescent protein (GFP) was supplied by University 
of Applied Sciences of Jena (Jena, Germany, 
concentration = 1 mg/mL). Rhodamine B (RhB) was 
obtained from Sigma-Aldrich. Phosphate buffered 
saline (PBS, pH=7.4) was purchased from life 
technologies in UK. Deionized water was purchased by 
VWR international. 
Methods 
Preparation of Magnetic Nanobiocomposites (NBC) 
NBC were prepared by solution casting method 
[14]. Briefly, 1.98 g dextran myristate dissolved in 5 
mL tetrahydrofuran (THF) were mixed with 0.02 g 
oleic acid coated MNPs. The suspension formed was 
treated in an ultrasonic bath (Elma Transsonic 460/H, 
35 kHz) for 20 min. It was poured into a petri dish and 
a film (thickness < 1 mm) was formed under airflow. 
The NBC was collected in form of granulates and dried 
in vacuum for 2 days. Dextran palmitate magnetic 
composite was prepared in comparable procedure. For 
investigations of the stability, 50 mg NBC granulate 
was filled into a mold and the temperature was 
increased to 50 °C for 20 min in an oven forming a 
composite disk after solidification. The disk samples 
had a radius of 3 mm and thickness of about 2 mm. 
Preparation of NBC Containing GFP 
NBC (50 mg) was filled into a blister pack with 
radius of 3 mm and thickness of 4 mm. The 
temperature was increased to 50 °C for 20 min in an 
oven forming a composite disk after solidification. 20 
µL GFP solution (1 mg/mL) was dropped on the 
composite with micropipette. The GFP solution was 
allowed to dry under air for 2 h to form a layer on the 
composite surface. Subsequently, another 50 mg 
magnetic dextran myristic ester was added on the GFP 
layer and the temperature was increased to 50 °C for 
20 min in an oven. After cooling, a disk shape GFP 
loaded NBC (radius of 3 mm and thickness of 4 mm) 
was formed (see Fig. S1). The composites were stored 
in the dark at 4 °C. The composite was kept in the 
blister to ensure a constant surface area to PBS medium 
during the controlled release experiment. 
Preparation of NBC Containing RhB 
Dextran ester (1.96 g) and 0.02 g RhB were 
dissolved in 10 mL THF and 0.02 g oleic acid coated 
MNPs were added. The suspension formed was treated 
in an ultrasonic bath (Elma Transsonic 460/H, 35 kHz) 
for 30 min. It was poured into a petri dish and a film 
(thickness < 1mm) was formed under airflow. The RhB 
containing NBC was collected in form of granulates 
and dried for 2 days in vacuum. RhB containing NBC 
(50 mg) was filled into a blister pack with a radius of 3 
mm and thickness of 4 mm (see Fig. S1). The 
temperature was increased to 50 °C for 20 min in an 
oven forming a composite disk after solidification. The 
NBC were stored in the dark at 4 °C. The 
nanobiocomposite was kept in the blister during the 
controlled release experiment. 
The samples for the controlled release 
experiments are summarized in Table 1. 
Differential Scanning Calorimetry (DSC) of NBC 
Magnetic myristate nanobiocomposite (10 mg) 
was investigated with a DSC equipment (Netzsch DSC 
204 F1 Phoenix) in an aluminum pan under nitrogen 
environment. The heating rate was 10 °C/min and 
cooling rate was 20 °C/min. Samples were first cooled 
to -30 °C and heated up to 200 °C. The heating/cooling 
cycles were carried out for three times. 
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Biodegradation of NBC using Artificial Body Fluids 
The biodegradability of the NBC was tested in 
different artificial body fluids simulating a 
physiological environment according to published 
procedures [21-23] in order to determine the iron 
release from the incorporated MNPs as a measure for 
the stability. Simulated body fluid (SBF, pH 7.4) and 
artificial lysosomal fluid (ALF, pH 4.5) were used to 
simulate the plasma or lysosomal compartment, 
respectively. The solutions were sterile filtered (0.2 µm 
filter) after pH adjustment. For degradation testing the 
composites (1% m/m MNP) were incubated in 10 mL 
ALF or SBF each for 28 days at 37 °C and 110 rpm in 
an incubation shaker (IKS 4000ic control, IKA-Werke, 
Germany). After 1, 2, 4, 8, 24, 48, and 72 h as well as 
after 7, 14, 21, and 28 days, 1 mL supernatant was 
collected and replaced with 1 mL of fresh ALF or SBF. 
The samples were stored at 4 °C for further analysis of 
iron content. The released iron was measured by 
bathophenanthroline disulfonic acid (Thermo Fisher, 
Germany) complexation and spectroscopic 
quantification (n=3) at 535 nm using a multiwell-plate 
reader (Spark 10M, Tecan Group, Switzerland) 
according to a modified method of Arbab et al. [21]. 
For measurements in SBF, solutions were acidified 
with an aqueous 5 mM citric acid solution for 
absorption stabilization. Iron concentrations were 
normalized in dependency on an iron (III) citrate 
(Sigma-Aldrich, Germany) standard curve (up to 0.06 
mmol/L). The cumulatively released iron amount was 
calculated at each time point. The corresponding 
artificial body fluids (ALF, SBF) were used as blanks. 
The experiments were repeated once (SBF) or twice 
(ALF). Data are presented as the mean ± standard 
deviation (SD) of all experiments. 
Thermal Treatment of Samples Externally with 
Water Bath and Internally with Alternating Magnetic 
Field 
Stock solution of GFP were diluted with HPLC 
water to a concentration between 1 and 10 ng/mL and 
measured in a 10 mm path-length quartz cuvette 
(Helma 111-QS, Germany). The emission wavelength 
maximum at λ = 510 nm of GFP was measured with 
fluorescent spectrometer (Perkin Elmer LS50-B, UK) 
with excitation at 400 nm. 
Stock solutions of Rhodamine B were diluted with 
HPLC water to a concentration between 0.5 and 5 
mmol/L and measured in a 10 mm path-length cuvette. 
The amount of RhB was determined with 
spectrophotometry (Lambda 950 UV/Vis/NIR 
spectrometer, Perkin Elmer) by measuring the 
absorption at 544 nm. Data is shown as mean ± SD       
(n = 3). 
The NBC disks filled in the blister pack (samples 
R4-R6, Table 1) were placed in a 15 mL polypropylene 
tube containing 3 mL PBS solution (pH value of 7.4). 
The polypropylene tube was heated in a water bath at 
42 °C for 12 min. After 1 h, the PBS solution was 
removed and diluted with PBS (to meet the linear 
fitting concentration range of calibration curve). PBS 
was filled into the tube and it was heated in a water bath 
at 42 °C for 12 min. NBC (samples R7-R9 and R13-
R15, Table 1) loaded with model drugs were put in the 
polypropylene tubes containing 0.5 mL PBS solution 
and placed in the middle of coil in AMF (3 turns, 5.5 
cm diameter, water cooling).  
 
Table 1. Samples of nanobiocomposites for controlled 
release studies (dextran myristate containing 1% 
magnetic nanoparticles) 
 
AMF was turned on for 12 min for each exposure 
(field amplitude of 20 kA/m and frequency of 400 
kHz). After 48 min PBS solution was removed and 
diluted with HPLC water. PBS was filled into the tube 
and next AMF was applied for 12 min. For studying 
the release of RhB for the 60 days (R19-R21), the tube 
was heated for 12 min at 42 °C externally in each cycle, 
in order to adjust the heating time with the samples 
heated with AMF (R22-R24). After 4 h, the sample 
was removed for analyzing. The temperature of the 
composite was determined with a fiber optical sensor 
(OPTOcon, Dresden, Germany). Control samples (R1-
R3, R10-R12 and R16-R18) were placed in 
polypropylene tubes at 25 °C without any heat 
treatment. Cumulative release was quantified as mass 
released at time t, Mt, over the total mass loaded, Msum. 
Data are shown as mean ± SD (n = 3). 
 
Sample 
No. Model drug 
Heating 
source 
Duration 
of release 
(h) 
Duration of 
AMF within 
release time 
(min) 
R1-R3 Rhodamine B No 6 - 
R4-R6 Rhodamine B Water bath 6 - 
R7-R9 Rhodamine B Alternating 
magnetic field 
6 36 
R10-R12 Green 
fluorescent 
protein 
No 8 - 
R13-R15 Green 
fluorescent 
protein 
Alternating 
magnetic field 
8 36 
R16-R18 Rhodamine B No 1440 - 
R19-R21 Rhodamine B Water bath 1440 - 
R22-R24 Rhodamine B Alternating 
magnetic field 
1440 72 
Heinze, et al. Indones. J. Fundam. Appl. Chem., 4(1), 2019, 1-8
 
DOI: 10.24845/ijfac.v4.i1.01  4   
 
RESULT AND DISCUSSION 
Preparation and Thermal Properties of 
Bionanocomposites (NBC) 
Esterification of dextran with fatty acids is a path 
to convert the biopolymer into a thermoplastic 
material. The thermoplastic constitutes a matrix 
polymer for the preparation of remote-controlled 
release systems that can be load with magnetic 
nanoparticles [13,14]. It is expected that the NBC 
undergoes a softening/melting above human body 
temperature under exposure of an alternating magnetic 
field (AMF), leading to an accelerated release of drugs 
loaded.  
Dextran myristic- and dextran palmitic acid ester 
with degree of substitution (DS) of 2.76 and 2.69, 
respectively, were chosen as polymer matrix, because 
they are solids at 37 °C and show softening (melting) 
above human body temperature. Above the melting 
temperature, the viscosity of the pure esters drops 
down to about 1 Pa.s at 100°C [14]. 
On the contrary to hydrogels, the dextran esters 
possess high DS of long hydrocarbon chains. Thus, 
they are hydrophobic and insoluble in biological 
matrices. The incorporation of lipophilic MNPs (with 
oleic acid shell) and of lipophilic drugs should easy to 
be carry out. The thermal behavior of the magnetic 
NBC of dextran myristate was studied by differential 
scanning calorimetry (DSC). A broad endothermic 
signal occurs at 40 °C, with a maximum at 52 °C in the 
second and third run as shown in the Supporting 
Information (Fig. S2). The temperature maximum 
corresponds to the softening observed by investigation 
with optical microscope. The second and third runs are 
reproducible, indicating that the temperature range of 
softening is not changed after a heating/cooling cycle. 
In order to study the influence of the kind of 
heating (AMF or by simple water bath) of the NBC 
with respect to heating rate and accessible temperature, 
heating tests under certain “geometrical” arrangements 
like sample size, volume of water bath and position of 
sensor were carried out. It turned out that the 
temperature of an NBC disk floating in 0.5 mL water 
can be easily increased by AFM (Fig. 1).  
The temperature reached surpassed the melting 
range of the NBC after about 6 min. The AMF heating 
time was set as 12 min in order to melt the NBC. After 
cooling, the NBC solidified, and it could be molten 
again by increasing the temperature applying AFM.  
Stability of magnetic NBC in artificial body fluids 
The stability of magnetic NBC was assessed in two 
different artificial body fluids by measuring the iron 
release. Simulated body fluid (SBF) was used for the 
simulation of a neutral body environment (pH 7.4) that 
can be found in the blood stream, the extracellular 
matrix, or in the cytoplasm. 
 Figure 1. Temperature increase (measured with a 
fiber optical sensor) of a disk of the nanobiocomposite 
(1 wt.% magnetic nanoparticles) surrounded by 0.5 mL 
water subjected to continuous alternating magnetic 
field (AMF, strength of 20 kA/m and frequency of 400 
kHz). 
It is well known that iron oxide nanoparticles are 
degradable in lysosomes after systemic application by 
acidic disintegration mainly by iron chelating agents 
such as citrate [23,24]. To simulate the degradation of 
potentially released iron oxide particles from the NBC 
and to assess the shielding effect of the dextran fatty 
acid ester in acidic environments, artificial lysosomal 
fluid (ALF) as a complex artificial fluid was used [20]. 
Iron release from the incorporated MNPs was 
determined using bathophenantroline complexation to 
follow the degradation process quantitatively (Fig. 2). 
NBC stored in SBF released only 0.31% (dextran 
palmitate) or 0.19% (dextran myristate) of the total iron 
content indicating the stability of the MNPs in the 
NBC. The release of iron from NBC incubated in ALF 
over time was higher; a cumulative amount of 5.4% 
(dextran palmitate) or 2.17% (dextran myristate) was 
mobilized after 28 d at 37 °C. 
Thus, the pH value of the system influences the 
stability of NBC, which is in accordance with the 
results of Gutiérrez et al. [24] studying the dependency 
of the degradation behavior of MNPs on the pH value. 
Under similar pH conditions (pH value of 4.5), a 
considerable effect of the coating was revealed as well. 
It may assume that the hydrophobicity of the matrix 
prevents degradation by limiting the penetration of the 
aqueous simulation media into deeper regions of the 
composites and therefore only superficial areas or 
MNPs located on the surface of the composites 
degraded. This indicates a sufficient stability of the 
composites even at acidic conditions. Therefore, if 
applied as implants, the novel NBC could be used as 
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remote-controlled drug delivery systems. Moreover, 
their use for the induction of hyperthermia [25] over a 
long period since they show no relevant signs of 
degradation at neutral conditions seems to be possible. 
Obviously, the dextran fatty acid esters are able to 
protect the incorporated MNPs or possibly drugs from 
degradation even at acidic conditions (ALF). There 
were no significant differences regarding the stability 
of the composites between the two investigated 
polymers, it was decided to choose the dextran myristic 
ester for further experiments since it displays a lower 
softening/melting temperature (40 °C, myristic acid 
ester compared to 45 °C, palmitic acid ester). The 
lower temperature is beneficial since many drugs, as 
for example proteins, are thermos-sensitive and release 
of the drug could be achieved at lower temperatures. 
 
 Figure 2. Iron release from magnetic 
nanobiocomposites quantified by bathophenanthroline 
complexation and spectroscopic determination at 535 
nm (n=3). Experiments were run at 
37 °C, 110 rpm over 28 d. Results are shown as the 
mean of two (SBF) or three (ALF) independent 
measurements ± SD. 
Release of GFP and RhB in PBS Solution 
GFP was used as model drug with a large 
molecular weight compared to RhB. Moreover, GFP 
can be easily detected by fluorescence spectroscopy 
down to ng/mL. NBC containing GFP was obtained by 
the entrapment trapped in the NBC as dumpling-like 
structure without any external stimulus.  
Fig. 3 shows pulsatile release profiles of GFP from 
magnetic NBC (samples R13-15) induced by AMF 
compared to control samples (R10-12). There was no 
release of GFP at t0 and t1. After treating the sample by 
AMF for 12 min and for 48 min without AMF 
treatment, 5% of the GFP loaded was released from the 
NBC after 2 h. The release of the GFP was achieved 
after internal heating the NBC by AMF. After 3, 3.5 
and 4 h total running time without additional exposure 
to AMF, a release of GFP could be observed (squares, 
Fig. 3) that was low compared to the amount released 
under exposure of AMF after 2 h. By applying repeated 
treatments with AMF, the amount of GFP released 
could be increased (at 4.5 and 6.5 h). Therefore, the 
dumpling-like structure was open after first melting 
process and GFP can diffuse into the medium. The 
release starts after the sample was treated with AMF 
because GFP cannot penetrate the tightly fitted 
polymer layer due to its thickness of about 1 mm [14]. 
The advantage of the magnetic system is that leaking 
of drug can be avoided compared to a hydrogel system, 
where a drug release could be achieved by changing of 
water absorption resulting in a swelling/shrinking of 
matrix structure [6]. 
 Figure 3. Cumulative of GFP release from 
nanobiocomposite (released mass at time t over the 
total mass of GFP, m(t)/m) placed in phosphate buffered 
saline (PBS) solution (samples R13-R15). The 
samples were heated applying water bath (42 °C) or by 
alternating magnetic field (AMF) for 12 min interval. 
Control samples were kept at 25°C 
Disks of the NBC containing RhB prepared by the 
casting method as discussed were treated by AMF or 
by external heating using a water bath applying same 
duration and cycles of heating (samples R4-6, R7-9, 
R19-21, R22-24, see Table 1). The starting of the 
heating cycles in case of short term experiments 
(hours) are indicated in Fig. 4, for long term 
experiments (days) they are after 1, 2, 3, 7, 14, 30, and 
60 days shown in Fig. 5. As mentioned, different to the 
external heating in water bath, AMF generates a 
heating inside of the NBC. Release from the NBC 
containing RhB obtained under the different kind of 
heating shows a steady increase of released RhB at 
42°C (temperature above melting) by external heating, 
on one hand (Fig. 4). On the other hand, internal 
heating with AMF yield comparable amount of RhB 
released (about 2%) within two hours. Further AMF 
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treatment yield an increased amount of RhB released. 
It turned out that externally heating using a water bath 
yields a slightly higher amount of RhB released of up 
to 6 wt.% compared to AMF. At 25°C a release of RhB 
was observed as well; after six hours about 2 wt.% are 
released. 
 Figure 4. Cumulative mass of Rhodamine B released 
from nanobiocomposites over 6 h (square, 1 wt.% 
MNP under exposure to alternating magnetic field for 
12 min duration for one heating cycle; triangle, 1 wt.% 
MNP, heated at 42 °C; star, 1 wt.% MNP, control 
sample at 25 °C) in phosphate buffered saline, m(t) 
represents cumulative mass released at time t, m 
represents the total mass loaded. 
In long-term experiments, the cumulative RhB 
released is almost twice the amount compared to that 
of control samples treated at 25 °C after 60 days as 
shown in the Fig. 5. The amount of RhB released is 
comparable for samples stimulated by AMF and 
external heating by a water bath, considering the same 
heating cycles in both cases (12 min heating time per 
each cycle). It is occurred to the shorter effective time 
above the melting temperature in case of AMF heating. 
(see 3.3). The release rates of both heated samples 
(AMF-25° and Ex-25°) in Fig. 6 were calculated as the 
difference of mass released between the sample (R19-
21, R22-24) and the control sample (25°C, R16-18) 
over the cumulative heating time, which is considered 
as the effect of heating. The release rates of the heated 
samples are higher than that of the control sample, 
which means that the heating increased the diffusion 
rate. The cumulative release rate of the control sample 
over the total time is given in Fig. 6 as well. 
Interestingly, the rates are different at short release 
times of the samples heated by AMF and externally, 
i.e., surface effects might be dominant. The local heat 
distribution in the samples might be different. 
Applying an external heating (water bath), the NBC 
start to melt on the surface and, thus, the drug is 
released fast from the outer layers, whereas the melting 
starts inside the samples heated by AMF and due to 
heat dissipation the melting of the surface starts later 
providing homogeneous heating in samples with 
homogeneously distributed MNPs occurs. 
Additionally, local fluctuations of the MNP 
concentration in the µm-scale can lead to temperature 
gradients. Local overheating near particle clusters 
can’t be excluded. At long release times the time 
intervals between the heating cycles are bigger and the 
heating comes less important that can be seen on the 
parallel curves in Fig. 5 and the similar release rates of 
both heated samples in Fig. 6. Influences of the RhB 
concentration gradients on the release behavior over 
time might be possible however since the total released 
amount is quite small (<16%) the effect should be 
weak. 
 Figure 5. Cumulative mass released from Rhodamine 
B nanobiocomposite over 60 days (square, 1 wt.% 
MNP under exposure to alternating magnetic field for 
12 min duration for one heating cycle; triangle, 1 wt.% 
MNP, heated externally at 42 °C; star, 1 wt.% MNP, 
control sample at 25 °C) in phosphate buffered saline 
(pH 7.4), mt, represents cumulative mass released at 
time t, msum represents the total mass loaded. 
Comparison of the cumulative release of the two 
model drugs showed that the release of GFP from a 
container-like sample geometry (20%) was more 
efficient than that of RhB from a homogeneously 
loaded material (6%) in 6 days despite of the much 
higher molecular mass of GFP. The reason could be 
that melting of GFP NBC caused abrupt structure 
collapse of the sample container and resulted in a fast 
release of GFP, however, the design of RhB NBC 
results a homogeneous distribution of RhB. 
Nevertheless, even after 8 hours GFP was not 
completely released in PBS and about 80% of GFP 
may be still trapped in the polymer. The diffusivity is 
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largely influenced by the environmental temperature 
and concentration in medium. It seems that a pulsatile 
diffusion of loaded GFP can be switched on/off, while 
RhB composite shows a sustained release behavior. 
 Figure 6. Release rate of samples heated by alternating 
magnetic field (AMF - 25°C), calculated by difference 
of released mass between AMF heating and control 
sample over the cumulative heating time. Release rate 
of samples heated externally (Ex - 25 °C), calculated 
by difference of released mass between external 
heating sample and control sample over the cumulative 
heating time. 
CONCLUSION 
Meltable polysaccharide-based biopolymers can 
be applied to design magnetically remote-controlled 
systems for drug release. The thermoplasticity of the 
magnetic nanobiocomposites enables the fabrication of 
carriers by melt casting without using solvents to 
design different geometries. The dextran esters protect 
the MNPs incorporated from degradation in artificial 
body fluids displaying a long-term stability (up to 28 
days). GFP, i.e. compound of rather high molar mass 
can be immobilized in the NBC without leaking when 
no external thermal stimulus is applied compared to the 
hydrogel system. Increasing of temperature by AFM 
yield may accelerated diffusion of model drugs (GFP 
and RhB). This meltable and bio-based magnetic 
composite will be studied for the immobilization of 
drug and their controlled release by applying. 
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